Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 608.

https://doi.org/10.1182/blood-2024-207638

Published: 2024

Journal Articles

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2024-200050

Published: 2024

Journal Articles

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2024-193091

Published: 2024

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Active Primary Malignancy at HCT - a Bi-Institutional Retrospective Cohort Analysis

Ron Ram, Ido Wolf, Odelia Amit, Ronit Yerushalmi, Yakir Moshe, Noga Shem-Tov, Gil Fridberg, Ivetta Danylesko, Irit Avivi Mazza, Avichai Shimoni

Blood (2023) 142 (Supplement 1): 3590.

https://doi.org/10.1182/blood-2023-182826

Published: 2023

Journal Articles

High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia

Shalev Fried, Ivetta Danylesko, Ronit Marcus, Orit Itzhaki, Ronit Yerushalmi, Noga Shem-Tov, Inbal Sdayoor, Roni Shouval, Elad Jacoby, Meirav Kedmi, Arnon Nagler, Avichai Shimoni, Abraham Avigdor

Blood (2023) 142 (Supplement 1): 6875.

https://doi.org/10.1182/blood-2023-178477

Published: 2023

Journal Articles

Bisantrene in Combination with Fludarabine and Clofarabine As Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)- an Open-Label, Phase II, Study

Ivetta Danylesko, Avichai Shimoni, Abraham Avigdor, Meirav Kedmi, Noga Shem-Tov, Ronit Yerushalmi, Maya Sasson, Dan Dominissini, Borje S. Andersson, Arnon Nagler

Blood (2023) 142 (Supplement 1): 4292.

https://doi.org/10.1182/blood-2023-178286

Published: 2023

Journal Articles

Prediction of Sinusoidal Obstructive Syndrome after Allogeneic Stem Cell Transplantation Using Liver Stiffness Measurement By Fibroscan

Ivetta Danylesko, Yana Davidov, Noga Shem-Tov, Ronit Yerushalmi, Ziv Ben-Ari, Arnon Nagler, Avichai Shimoni

Blood (2023) 142 (Supplement 1): 3542.

https://doi.org/10.1182/blood-2023-179990

Published: 2023

Journal Articles

Allogeneic Stem Cell Transplantation with Myeloablative Compared with Reduced- Intensity Conditioning for AML and Mds; 20 Years Later

Avichai Shimoni, Ronit Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, Abraham Avigdor, Arnon Nagler

Blood (2023) 142 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2023-184520

Published: 2023

Journal Articles

Pre-Treatment Pulmonary Assessment Have Limited Utility in B-Cell Lymphoma Patients Treated with Autologous Anti-CD19 CAR T-Cell Therapy

Inbal Sdayoor, Roni Shouval, Shalev Fried, Ronit Marcus, Ivetta Danylesko, Ronit Yerushalmi, Noga Shem-Tov, Orit Itzhaki, Elad Jacoby, Meirav Kedmi, Arnon Nagler, Avichai Shimoni, Michael J Segel, Abraham Avigdor

Blood (2023) 142 (Supplement 1): 3519.

https://doi.org/10.1182/blood-2023-180115

Published: 2023

Journal Articles

The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy

Blood (2023) 142 (Supplement 1): 6908.

https://doi.org/10.1182/blood-2023-187338

Published: 2023

Journal Articles

Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 648–650.

https://doi.org/10.1182/blood-2022-162286

Published: 2022

Journal Articles

CXCR4 Promotes Bortezomib Resistance and Regulates Metabolic Reprogramming, Activating Both Glycolytic and Oxphos Pathways in Multiple Myeloma

Katia Beider, Noy Sharvit Boaron, Valeria Voevoda, Olga Ostrovsky, Ivetta Danylesko, Avichai Shimoni, Amnon Peled, Arnon Nagler

Blood (2022) 140 (Supplement 1): 5969–5970.

https://doi.org/10.1182/blood-2022-164646

Published: 2022

Journal Articles

Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study

Blood (2021) 138 (Supplement 1): 883.

https://doi.org/10.1182/blood-2021-147568

Published: 2021

Journal Articles

Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients

Shalev Fried, Ivetta Danylesko, Ronit Yerushalmi, Noga Shem-Tov, Roni Shouval, Joshua A Fein, Zachary Cohen, Elad Jacoby, Michal Besser, Arnon Nagler, Avichai Shimoni, Abraham Avigdor

Blood (2021) 138 (Supplement 1): 910.

https://doi.org/10.1182/blood-2021-147148

Published: 2021

Journal Articles

Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia

Ohad Benjamini, Avichai Shimoni, MD, Michal Besser, PhD, Noga Shem-Tov, MD, Ivetta Danylesko, MD, Ronit Yerushalmi, MD, Drorit Grizim Merkel, MD, Tamar Tadmor, MD, David Lavie, MD, Riva Fineman, MD, Elad Jacobi, MD, Arnon Nagler, MD, Abraham Avigdor, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-138904

Published: 2020

Journal Articles

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Chezi Ganzel, MD, Ron Ram, MD, Alexander Gural, MD, Ofir Wolach, MD, Sharon Gino-Moor, MD, Vladimir Vainstein, MD, Boaz Nachmias, MD PhD, Arie Apel, MD, Maya Koren-Michowitz, MD, Oren Pasvolsky, MD, Ronit Yerushalmi, MD, Ivetta Danylesko, Yoseph Cohen, MD, Galit Perets, Yakir Moshe, MD, Miri Zektzer, MD, Shay Yeganeh, MD, Jacob M. Rowe, MB, BS, Yishai Ofran, MD

Blood (2019) 134 (Supplement_1): 5091.

https://doi.org/10.1182/blood-2019-125662

Published: 2019

Journal Articles

Maintenance 5-Azactidine May Improve Outcomes after Allogeneic Stem-Cell Transplantation in High-Risk AML and MDS Patients

Ivetta Danylesko, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD MSc, Avichai Shimoni, MD

Blood (2019) 134 (Supplement_1): 3302.

https://doi.org/10.1182/blood-2019-129966

Published: 2019

Journal Articles

Lactate Dehydrogenase Is a Key Prognostic Factor in Acute Myeloid Leukemia and Lymphoma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Mika Geva, Roni Shouval, Joshua A Fein, MD, Ivetta Danylesko, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Avichai Shimoni, MD, Arnon Nagler, MD MSc

Blood (2019) 134 (Supplement_1): 3304.

https://doi.org/10.1182/blood-2019-125529

Published: 2019

Journal Articles

Early Organ Toxicity Following Allogeneic Hematopoietic Stem Cell Transplantation Differs By Conditioning Regimen

Joshua A Fein, MD, Avichai Shimoni, MD, Ivetta Danylesko, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Guy Chowers, MD, Zachary Cohen, Arnon Nagler, MD MSc, Roni Shouval

Blood (2019) 134 (Supplement_1): 4489.

https://doi.org/10.1182/blood-2019-126325

Published: 2019

Journal Articles

Oral Mucositis Is Associated with Distinctive Patterns of Oral Microbiota Injury in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Roni Shouval, Adi Eshel, MSc, Ivetta Danylesko, Bar Dubovski, Joshua A Fein, MD, Shalev Fried, Mika Geva, MD, Elizaveta Kouniavsky, Amir A Kuperman, MD MSc, Yoram Louzoun, PhD, Omry Koren, PhD, Arnon Nagler, MD MSc

Blood (2019) 134 (Supplement_1): 3265.

https://doi.org/10.1182/blood-2019-125433

Published: 2019

NARROW

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Active Primary Malignancy at HCT - a Bi-Institutional Retrospective Cohort Analysis

High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia

Bisantrene in Combination with Fludarabine and Clofarabine As Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)- an Open-Label, Phase II, Study

Prediction of Sinusoidal Obstructive Syndrome after Allogeneic Stem Cell Transplantation Using Liver Stiffness Measurement By Fibroscan

Allogeneic Stem Cell Transplantation with Myeloablative Compared with Reduced- Intensity Conditioning for AML and Mds; 20 Years Later

Pre-Treatment Pulmonary Assessment Have Limited Utility in B-Cell Lymphoma Patients Treated with Autologous Anti-CD19 CAR T-Cell Therapy

The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy

Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy

CXCR4 Promotes Bortezomib Resistance and Regulates Metabolic Reprogramming, Activating Both Glycolytic and Oxphos Pathways in Multiple Myeloma

Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study

Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients

Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Maintenance 5-Azactidine May Improve Outcomes after Allogeneic Stem-Cell Transplantation in High-Risk AML and MDS Patients

Lactate Dehydrogenase Is a Key Prognostic Factor in Acute Myeloid Leukemia and Lymphoma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Early Organ Toxicity Following Allogeneic Hematopoietic Stem Cell Transplantation Differs By Conditioning Regimen

Oral Mucositis Is Associated with Distinctive Patterns of Oral Microbiota Injury in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only